Fungi from more than 100 genera have been implicated in subcutaneous fungal infections, usually following traumatic inoculation of the etiologic agent. With the advent of molecular approaches to fungal identification and taxonomy, novel agents of subcutaneous mycoses are increasingly reported. In this manner, Roussoella percutanea, a novel species in Pleosporales, was described in 2014 from a subcutaneous mass in an immunocompetent male adult. Two additional cases involving renal transplant recipients were recently reported from patients resident in France and Germany, with several further cases discovered after analyses of historical culture collection isolates. Here, we describe a new case of subcutaneous R. percutanea infection, causing a mycotic cyst in a renal transplant patient resident in the UK. Although fungal infection was confirmed histologically, viable fungal isolates could not be recovered in culture from biopsy material and identification of the causative agent relied upon PCR amplification and sequencing of fungal rDNA genes. This is the fourth welldocumented case of infection with R. percutanea in renal transplant patients, and the first reported from a patient resident in the UK. The current case illustrates the importance of molecular approaches for the identification of emerging fungal pathogens in culture-negative subcutaneous fungal infections.
Introduction
Subcutaneous fungal infections usually occur following traumatic inoculation of the etiological agent into cutaneous or subcutaneous tissue. Although infections typically remain localised in immunocompetent individuals, without treatment they frequently become chronic, with gradual expansion to involve adjacent tissues and even bone [1] [2] [3] . This heterogeneous disease spectrum includes hyalohyphomycoses (infection by fungi with hyaline hyphae), phaeohyphomycoses (infection with melanised, dematiaceous fungi), chromoblastomycoses (characterised by formation of sclerotic bodies in tissue) and eumycetoma (characterised by extensive tumefaction with formation of purosanguinous sinuses extruding fungal grains) [2] [3] [4] [5] .
Fungi from more than 100 genera have been reported from subcutaneous mycoses in humans, with novel species and genera described almost weekly [5] . In some cases, the responsible fungi have only been reported from individual, isolated case reports suggesting that they are infrequent agents of subcutaneous infection [6] [7] [8] [9] . For many other species, they have been predominantly associated specifically with precise clinical presentations and have been rarely or never isolated from nature [2, 4, 5, [10] [11] [12] . Although certain species are predominantly associated with a specific clinical presentation, clinical picture is also determined by host immune status, with the result that accurate definition of disease entity may be difficult [13, 14] . In addition, many of the agents of subcutaneous mycoses exhibit reluctant conidiation in culture, especially when isolated from chronic cases [5, 10, 12, 14] . Since accurate identification of the causative agent is paramount in directing appropriate therapeutic interventions, molecular approaches using PCR amplification and sequencing of conserved regions of fungal genomic DNA are increasingly employed [14] [15] [16] [17] . Using such approaches, Roussoella percutanea, a novel species in Pleosporales, was recently described from a subcutaneous mass in an immunocompetent male adult [18] . Clinical presentation included hyphal masses with granulation tissue and fibrosis, but draining sinuses typical of eumycetoma were absent. A retrospective analysis of other culture collection isolates revealed one further historical isolate of R. percutanea, from a pedal mass in a renal transplant patient who also presented with necrosis and inflammation but without draining sinuses or fungal grains [13, 18] . More recently, two additional cases of R. percutanea subcutaneous infection have been reported, both affecting renal transplant recipients and again both without the sinus or grain formation characteristic of eumycetoma [19, 20] . Additional examples of Roussoella species from human infections have also been identified in a recent molecular study of coelomycetous fungi in the clinical setting in the USA [21] . In all cases where viable organism could be recovered from biopsy material, conidiation in culture was delayed or absent. Although variable antifungal susceptibility profiles were reported for some of the previous isolates [18] [19] [20] , in general the triazole antifungals showed the highest in vitro activity against this species [18, 20] .
Here, we present the first case of R. percutanea infection from the UK, involving a subcutaneous cyst from a renal transplant patient. Attempts to culture the organism from cyst tissue were unsuccessful and diagnosis and identification were achieved by PCR amplification and sequencing of fungal genomic DNA from biopsy material.
Case History
A 47-year-old male, originally from Surat, Gujarat, but residing in the UK since 1997, underwent a renal transplant in November 2015 for end-stage renal failure of unknown cause. Post-operatively, he was immune-suppressed with oral prednisolone 12.5 mg once a day and tacrolimus 5 mg twice daily and commenced prophylactic oral co-trimoxazole and aciclovir. Other past medical history included gout, osteoarthritis, an inguinal hernia and migraines.
Post-transplantly, he suffered from an episode of declining renal function secondary to borderline T cell mediated rejection, requiring two rounds of pulsed methylprednisolone and addition of mycophenylate mofetil 500 mg twice daily to his immunosuppressive regimen from January 2016. His clinical course was also complicated by multiple episodes of urosepsis, including one episode of bacteraemia, due to an extended-spectrum b-lactamase producing Klebsiella pneumoniae, between January and May 2016.
During admission for an episode of Klebsiella urosepsis in March 2016, an incidental finding was made of a mobile, soft tissue mass over the right Achilles tendon. The lesion was non-tender and not adherent to the tendon itself with no masses elsewhere or evidence of lymphatic involvement or sinus tract formation. The patient had been unaware of the lesion, and it had not caused him any pain or symptoms. Clinical suspicion of mycetoma was raised. An ultra-sound scan confirmed a 2 by 1.5 centimetre heterogeneous nodule overlying but separate from the Achilles tendon. A biopsy of the lesion was performed which did not reveal any organisms on Gram stain, and there was no growth by conventional bacterial culture (including Sabouraud's dextrose agar). Histology revealed a diffuse macrophage infiltrate with cytoplasmic inclusions, and fungal hyphae were seen on Periodic acid-Schiff and Periodic acidSchiff-diastase stains (Fig. 1) . Empirical antifungal treatment was not started at this point due to the patient's stable clinical condition.
Microscopic analysis of biopsy material by potassium hydroxide digestion with Calcofluor enhancer (Bactidrop, Remel) revealed the presence of moderate amounts of filamentous fungal elements (Fig. 2) . These were generally amorphous and included fine, regularly septate and acutely branching hyphae, which were hyaline to light brown together with more common short chains of swollen cells and chlamydospores. Despite prolonged culture on a variety of mycological media, no viable fungal isolate could be recovered for further analyses. Small sections (2-4 mm 3 ) of unfixed biopsy tissue were subjected to digestion and Qiagen column purification (Qiagen Mini Blood kit) and PCR amplification of the 28S rDNA and Internal transcribed spacer 1 (ITS1) regions of the resulting extracted fungal genomic DNA using the PCR primers and conditions described previously [12, 14, 17] . The sequences of the resulting PCR amplicons (amplicon lengths 387 and 234 bp, respectively, for the 28S and ITS1 regions) were 100% identical (355/355 bp query coverage for 28S and 202/202 bp identity for ITS1) to those of the type species of Roussoella percutanea (isolate CBS128 203; GenBank accession numbers KF366448 and KF322117) present in the public synchronised NCBI GenBank database. Treatment with oral voriconazole 200 mg twice a day was then immediately commenced and total excision of the lesion took place with 5 mm margins. Histology of the excised lesions confirmed fungal hyphae on both Hematoxylin/Eosin and Grocott stains. Unfortunately, due to clinical concern regarding potential interactions between voriconazole and tacrolimus, and a falling neutrophil count (to a trough of 2.1 9 10 9 /l), while being treated with voriconazole, antifungal treatment was discontinued after only 2 weeks. Despite this, the patient's wound was healing and dries at 6 weeks post-excision with no evidence of recurrence so far.
Discussion
We report here the first known UK case of subcutaneous infection by R. percutanea. We have no concrete explanation as to why we were unable to recover viable fungus from biopsy specimens in the current case, since appropriate media and incubation temperatures and times were employed. However, it is possible that small sample size and an uneven distribution of scant fungal elements throughout the tissue (Figs. 1, 2 ) might have resulted in viable organism not being present in the portions of specimen that were subjected to culture. Previous reports of infections with R. percutanea highlighted the utility of molecular identification even when viable fungus was recovered, due to the difficulty in inducing production of characteristic features required for conventional identification [19, 20] . In the current case, we are confident that R. percutanea is the causative pathogen rather than an artefact due to PCR contamination. Although it is clear that R. percutanea does exist in the environment, we have never previously encountered this organism either as a laboratory plate contaminant or in PCR in any of the thousands of samples processed by the Mycology Reference laboratory each year. Moreover, the clinical presentation and patient history in the current case are entirely consistent with previous reported cases of subcutaneous infections with R. percutanea [18] [19] [20] . Interestingly, of the five clearly documented cases reported worldwide, the current case is the fourth to have affected a renal transplant patient [13, [18] [19] [20] . In all four cases, presentation differed from that seen with eumycetoma due to the presence only of inflammatory infiltrates and discrete fungal elements and absence of fungal grains or draining sinuses. Subcutaneous mycoses in immunocompetent patients frequently present diagnostic challenges due to the heterogeneous nature of clinical presentations and the fact that clinically detectable infections can take years to develop. This situation is further compounded in transplant patients, where relatively dormant fungi that have been harboured subcutaneously for many years or decades become clinically active after immunosuppression. Although most subcutaneous mycoses are thought to result from traumatic inoculation, it is hardly surprising given this protracted and Fig. 2 Calcofluor white staining of biopsy material that had been digested with potassium hydroxide. Magnification is the same in all four panels; scale bar = 10 lm variable incubation period that most patients are unable to recall any history of injury at the affected sites. This was the case with the current patient and with the previous reports of R. percutanea subcutaneous mycoses published to date [13, [18] [19] [20] .
Previous reports have suggested strain-specific variations in antifungal susceptibility in R. percutanea [18] , indicating that specific testing of patient isolates should be used to guide antifungal therapeutic decisions. Since the current case was culture-recalcitrant and no isolate was available for testing, the patients was treated with total excision of the lesion and commenced on voriconazole therapy. Unfortunately, antifungal therapy was stopped after only 2 weeks due to drug interactions. Although the patient is currently well, close follow up will be required, especially in the light of the reports of recurrences in several previous cases of R. percutanea infection [13, 18] .
In summary, the current case further highlights the utility of molecular diagnostic and identification approaches in medical mycology, especially in cases of subcutaneous fungal infections where conventional identification approaches are hindered by difficulties in recovering viable fungi from biopsy samples and organisms that fail to produce distinctive features in culture.
